Vitality Biopharma Sparks Canadian Cannabinoid Genetics R&D

Canada’s role in the emerging cannabinoid revolution just took another step forward this week—further highlighting that the country will be at the forefront of development for the foreseeable future.

The makers of a new form of cannabinoid prodrugs called “cannabosides,” have officially announced they’re launching a Canadian subsidiary focused on cannabinoid genetics research and development.

Vitality Biopharma, Inc. (OTC: VBIO) announced the formation of a wholly-owned Canadian subsidiary, Vitality Genetics, Ltd., which will focus on and enable the performance of a wide variety of cannabinoid R&D programs.

The company’s current flagship property is its proprietary cannabosides prodrugs, which facilitate the unlocking of the full potential of cannabinoids for the treatment of serious ...View the full post at: Vitality Biopharma Sparks Canadian Cannabinoid Genetics R&D ...

Related Articles:

Taking Advantage Of The Biggest Blunder In Oil

Meet Canada’s Massive Cannabis Greenhouse Spaces

Big Pharma says It Must Collaborate with Juniors to Revive Real Innovation

Market Trends Show Opportunities For Investors

Sign Up

Get the InvestingChannel
Free e-Letter Today

Learn More

Independent market opinion, analysis and ideas - delivered every business day

Premium market opinions, analysis, and ideas - delivered every business day

Editor's Picks